Rallybio CORP

Market Movers (8-K)

See all →
NASDAQ
Rallybio Corporation anticipates its merger with Avenzo Therapeutics to close on November 20, 2026, alongside detailed procedures for a $13.90 per share special cash distribution and Nasdaq listing approval.
NASDAQ
Rallybio Corporation is implementing a one-for-two reverse stock split, effective November 20, 2026, in preparation for its merger with Avenzo Therapeutics, Inc., after which the combined entity will be renamed Avenzo Therapeutics, Inc. and trade under the symbol AVZO.
NASDAQ
Rallybio Corporation has postponed the closing of its merger with Avenzo Therapeutics, Inc. due to unmet listing condition requirements.
Delay expected
Worse than expected
NASDAQ
Rallybio Corporation's shareholders overwhelmingly approved key proposals at their annual meeting, paving the way for a merger with Avenzo Therapeutics, Inc. and the adoption of new equity incentive and employee stock purchase plans.
Capital raise
NASDAQ
Rallybio Corporation details a special cash distribution of approximately $82.7 million in connection with its previously announced merger with Avenzo Therapeutics.
NASDAQ
Rallybio Corporation announces Chief Financial Officer Jonathan Lieber's transition to a part-time role effective September 15, 2026, with continued duties and specific compensation terms.

Quarterly Earnings (10-Q)

See all →
NASDAQ
Rallybio Corporation's Q3 2026 filing reveals a pending merger with Avenzo Therapeutics, Inc., ongoing operational losses, and a cash balance sufficient for over 12 months, bolstered by a recent termination fee.
Worse than expected
Capital raise
NASDAQ
Rallybio Corporation filed its Form 10-Q for the quarter ended June 30, 2026, detailing financial results, ongoing merger plans with Avenzo Therapeutics, and operational updates.
Capital raise
NASDAQ
Rallybio Corporation achieved net income in Q3 2025 driven by a strategic joint venture sale, extending its cash runway through 2027 while advancing its lead rare disease programs.
Capital raise
Better than expected
NASDAQ
Rallybio Corporation significantly reduced its net loss and operating expenses in Q2 2025, extending its cash runway into mid-2027, despite discontinuing its RLYB212 program.
Better than expected
Capital raise
NASDAQ
Rallybio announces Q1 2025 financial results, highlighting progress in RLYB116 development and pipeline prioritization.
Capital raise
Worse than expected
NASDAQ
Rallybio Corporation released its third quarter 2024 financial results, highlighting progress in its clinical programs and strategic collaborations.
Worse than expected
Capital raise

Annual Reports (10-K)

NASDAQ
Rallybio Corporation announces a definitive merger agreement with Candid Therapeutics, shifting its strategic focus to T-cell engager therapeutics and monetizing legacy assets through Contingent Value Rights.
Worse than expected
Capital raise
NASDAQ
Rallybio's 10-K filing summarizes the company's financial performance for 2024 and provides updates on its clinical development programs, including RLYB212 and RLYB116.
Worse than expected
NASDAQ
Rallybio's 2023 annual report highlights the company's progress in clinical development, particularly for RLYB212 and RLYB116, while also outlining strategic shifts and financial results.
Worse than expected
Capital raise

Insider Trading (Form 4)

See all →
NASDAQ
Rallybio Corporation announces its anticipated merger closing date of November 20, 2026, alongside detailed procedures for a $13.90 per share cash distribution, including Nasdaq's due bill process.
NASDAQ
Rallybio Corporation is implementing a one-for-two reverse stock split, effective November 20, 2026, in preparation for its merger with Avenzo Therapeutics, Inc., after which it will be renamed Avenzo Therapeutics, Inc.
NASDAQ
Rallybio Corporation announced the postponement of its merger closing with Avenzo Therapeutics, Inc. due to unmet listing approval conditions.
Delay expected
Worse than expected
NASDAQ
Martin Mackay, a Director of Rallybio Corp, reported multiple transactions in common stock on November 4, 2026.
NASDAQ
Ronald Hunt, a Director of Rallybio Corp, reported multiple transactions in common stock on November 4, 2026.
NASDAQ
Jonathan I Lieber, Chief Financial Officer of Rallybio Corp, reported multiple transactions in common stock on November 2, 2026.

Proxy Statements (Def-14A)

NASDAQ
Rallybio Corporation seeks stockholder approval for a reverse stock split to maintain its Nasdaq listing and enhance stock marketability.
Worse than expected
NASDAQ
Rallybio Corporation announces its 2025 Annual Meeting of Stockholders to be held virtually on May 13, 2025, with key proposals including the election of directors and ratification of the company's independent accounting firm.
NASDAQ
Rallybio Corporation announces its 2024 Annual Meeting of Stockholders to be held virtually on May 15, 2024, to elect directors and ratify the selection of its independent accounting firm.

Schedule 13D - Activist Investments

NASDAQ
Venture capital firm 5AM Ventures has disclosed the sale of approximately 291,788 shares of Rallybio Corp common stock.
NASDAQ
5AM Ventures and its affiliates have filed an Amendment No. 2 to their Schedule 13D, reporting a reduction in their beneficial ownership of Rallybio Corp common stock following recent open market sales.
Worse than expected

Schedule 13G - Passive Investments

See all →
NASDAQ
Cormorant Asset Management, LP and Bihua Chen have reported a 0.0% beneficial ownership of Rallybio Corp. common stock, indicating a complete divestment.
NASDAQ
Balyasny Asset Management L.P. and affiliated entities have filed a Schedule 13G amendment, reporting zero shares beneficially owned in Rallybio Corp.
NASDAQ
FMR LLC and Abigail P. Johnson have reported beneficial ownership of 15.0% of Rallybio Corp's common stock as of June 30, 2026.
NASDAQ
ADAR1 Capital Management and Daniel Schneeberger have reported a 17.5% beneficial ownership stake in Rallybio Corporation.
NASDAQ
Viking Global Investors LP filed an amendment to its Schedule 13G, reporting a 9.99% beneficial ownership stake in Rallybio Corporation.
NASDAQ
Nantahala Capital Management, LLC and its principals have reported a 5.68% beneficial ownership stake in Rallybio Corporation.